Adjuvant therapy for pancreas adenocarcinoma

Authors

  • Eileen M. O'Reilly MD

    Corresponding author
    1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    2. Weill Medical College of Cornell University, New York, New York
    • Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, Office 1021, New York, NY 10065. Fax: 646 888-4254.===

    Search for more papers by this author
    • Associate Attending, Memorial Sloan-Kettering Cancer Center; Associate Professor of Medicine, Weill Medical College of Cornell University.


Abstract

Adjuvant therapy for pancreas adenocarcinoma in 2012 includes consideration of systemic therapy based on high level evidence and combined chemoradiotherapy based on less robust data. Current major adjuvant questions are examining the role of the addition of a second agent, either cytotoxic or targeted agent, to gemcitabine and whether or not the utilization of combined chemoradiotherapy improves overall survival. Progress to date has been modest and incremental in the adjuvant setting. J. Surg. Oncol. 2013;107:78–85. © 2012 Wiley Periodicals, Inc.

Ancillary